Briakinumab

• CAS Number: 0339308-60-0

Briakinumab ( ABT- 874) is a monoclonal antibody ( psoriasis) was developed by the pharmaceutical company Abbott Laboratories as a drug for the treatment of psoriasis. In January 2011, the already asked approval application was withdrawn.

Mechanism of action

Psoriasis is a chronic inflammatory autoimmune disease of the skin characterized by excessive growth of keratinocytes ( skin-forming cells) in the epidermis. Possible triggers can environmental influences such as sunburn or bacterial antigens include that stimulate keratinocytes to increased production of inflammatory mediators. This triggers a series of consecutive reactions in the underlying epidermis dermis, including the expression of adhesion molecules on endothelial cells of small blood vessels, resulting in the migration of neutrophils and T lymphocytes and consequently to further distribution of inflammatory cytokines.

The distributed by macrophages and dendritic cells cytokines include IL -12 and IL- 23rd Both cytokines are heterodimeric protein, where the so-called p40 subunit is common. With the p40 subunit both bind to the IL- 12ß1 receptor of T- lymphocytes, which thereby make additional pro-inflammatory substances and promote the inflammatory process in psoriasis. Briakinumab should intervene in this process by binding to the p40 subunit of IL -12 and IL -23, thereby inhibiting the inflammatory subsequent processes.